GLP-1R agonist therapies have low rates of hypoglycaemia and are also associated with weight loss and not weight gain (with current dosages used in therapies), which is an undesirable side effect of some other glucose-lowering therapies4,6. The gene discussed is GLP1R; the disease is Hypoglycemia.